High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score
Jazyk angličtina Země Japonsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- analýza přežití MeSH
- antigen CA-125 krev MeSH
- dospělí MeSH
- folikulární lymfom diagnóza mortalita terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- prognóza MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- radioterapie MeSH
- senioři MeSH
- staging nádorů MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antigen CA-125 MeSH
Carbohydrate antigen-125 (CA-125) was established as a prognostic marker in cancer, especially in ovarian carcinoma. Many recent studies have also reported on the prognostic significance of CA-125 in patients with different types of lymphoma, but only a few studies have been carried out in patients treated with rituximab or high-dose therapy. The prognostic impact of CA-125 on a large cohort of patients with follicular lymphoma (FL) has not been studied. This study analyzed the prognostic significance of CA-125 levels in 116 prospectively enrolled patients with previously untreated FL. It showed that the CA-125 level at the time of treatment initiation correlates with the clinical stage, number of involved nodal areas, bulky disease, hemoglobin level, beta-2 microglobulin level, and lactate dehydrogenase level. Patients with CA-125 >35 U/mL had significantly shorter progression-free (p < 0.001) and overall (p = 0.025) survival rates. Cox regression analysis identified high CA-125 levels as a prognostic factor for overall (HR 3.04, p = 0.05) and progression-free (HR 3.55, p < 0.001) survival rates independent of FLIPI score variables. CA-125 levels may help to refine risk assessment in the modern immunotherapy era.
Zobrazit více v PubMed
Clin Oncol (R Coll Radiol). 1994;6(2):137 PubMed
Blood. 2006 Jan 1;107(1):265-76 PubMed
Int J Lab Hematol. 2010 Dec;32(6 Pt 2):582-9 PubMed
Eur J Cancer. 1990;26(7):858 PubMed
Br J Haematol. 1997 Aug;98(2):450-2 PubMed
Int J Gynecol Pathol. 1983;2(3):275-85 PubMed
Blood. 2006 Sep 1;108(5):1504-8 PubMed
Int J Hematol. 2010 Sep;92(2):246-54 PubMed
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):63-6 PubMed
Eur J Haematol. 2007 May;78(5):399-404 PubMed
Ann Oncol. 2004 Oct;15(10):1484-9 PubMed
Leuk Lymphoma. 2010 Sep;51(9):1754-7 PubMed
J Clin Oncol. 1999 Apr;17(4):1244 PubMed
Clin Adv Hematol Oncol. 2008 Jul;6(7):527-31 PubMed
J Clin Oncol. 1999 Aug;17(8):2499-505 PubMed
Blood. 2004 Sep 1;104(5):1258-65 PubMed
Gastric Cancer. 2012 Apr;15(2):154-61 PubMed
Ann Oncol. 2009 Oct;20(10):1697-702 PubMed
J Clin Oncol. 2005 Aug 1;23(22):5019-26 PubMed
J Egypt Natl Canc Inst. 2009 Sep;21(3):209-17 PubMed
Haematologica. 1998 Sep;83(9):800-11 PubMed
N Engl J Med. 1983 Oct 13;309(15):883-7 PubMed
N Engl J Med. 1993 Apr 8;328(14):1002-6 PubMed
Ann Oncol. 2000 Nov;11(11):1485-91 PubMed
Int J Biol Markers. 2008 Oct-Dec;23(4):207-13 PubMed
Cancer Prev Res (Phila). 2011 Sep;4(9):1356-9 PubMed